The Swiss biotech startup develops therapeutic cancer vaccines. AMAL Therapeutics will initiate an international Phase Ib clinical study to evaluate the combination of its lead candidate with Boehringer Ingelheim’s compound in patients with stage IV colorectal cancer. The study will begin in the second half of 2019.
AMAL Therapeutic’s lead candidate ATP128, is a chimeric recombinant protein designed using AMAL’s proprietary vaccine technology platform KISIMA. ATP128 comprises of a cell penetrating peptide for antigen delivery, a TLR peptide agonist for self-adjuvanticity and a multiple antigenic domain. ATP128 is designed to treat colorectal cancer.
The first-in-human study will investigate the safety and tolerability of ATP128 as single agent and in combination with Boehringer Ingelheim’s anti PD1 compound, BI754091, as primary objective. The anti-tumor activity and the characteristic of the immune response will be evaluated as secondary and exploratory objectives.
«We are excited to evaluate ATP128 in combination with BI754091 in different patient populations with stage IV colorectal cancer, and to show the value of our lead candidate and the potential of the KISIMA platform», says Madiha Derouazi, CEO and founder of AMAL Therapeutics.
The clinical study will be sponsored by AMAL while Boehringer Ingelheim will provide the trial with BI754091. The study results will be jointly owned. Furthermore, AMAL will retain full development and commercialization rights to ATP128 and the KISIMA technology platform.
(Press Release)
(Picture: Pixabay)
Please login or sign up to comment.
Commenting guidelines